The Comparative Study on the Effect of Ilaprazole and Esomeprazole for Laryngopharyngeal Reflux
- Conditions
- Diseases of the respiratory system
- Registration Number
- KCT0006492
- Lead Sponsor
- Dong-A University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 50
1) Male or female over 19 years of age and under 70 years of age
2) Laryngeal reflux (LPR) patients with reflux observation score (RFS) of 7 or more and reflux symptom index (RSI) of 13 or more
character
3) Those who agreed to participate in this study and voluntarily signed the written consent
4) Those without dementia or cognitive impairment
1) Those with a history of allergic symptoms (rash, fever, itching, etc.) or hypersensitivity reactions to this research drug
2) Those with confirmed malignant tumor or infection of the larynx
3) Those taking Atazanavir or Rilpivirine
4) 3 months of study participation with another proton pump inhibitor (PPI) or H2 receptor aatagonist (H2RA)
those who took it within
5) Those with a history of Zollinger-Ellison syndrome (ZES), alcoholism, or substance abuse
6) Pregnant and lactating women
7) Those who have participated in a clinical trial within 6 months of participating in the study
8) Those who are judged inappropriate by the researcher to participate in the research for other reasons
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of improvement in the reflux symptom index (RSI) of the ilaprazole group and the esomeprazole group
- Secondary Outcome Measures
Name Time Method Comparison of the improvement in the reflux findings score (RFS) between the ilaprazole group and the esomeprazole group